Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321877253> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2321877253 abstract "8579 Background: The ERIVANCE BCC study is the pivotal trial of vismodegib (GDC-0449), a first-in-class small-molecule inhibitor of Hedgehog signaling, for treatment of locally advanced (laBCC) and metastatic BCC (mBCC), for whom there are no other effective therapy options. The study met the primary endpoint of overall response rate by independent review (Sekulic, Melanoma Res 2011). Here we report a 6-mo update of investigator-assessed (I-A) efficacy and safety endpoints as of May 26, 2011. Methods: This multicenter, international, nonrandomized 2-cohort study enrolled patients (pts) with laBCC (deemed inoperable or for whom surgery would be significantly disfiguring), and mBCC pts with RECIST-measurable disease. Pts received 150 mg oral vismodegib daily. Results: 104 pts (71 laBCC/33 mBCC) enrolled at 31 sites in the US, Europe, and Australia. I-A efficacy endpoints are shown in the table. One-year survival rate was 77.3% (95% CI 62.48–92.09%) for mBCC and 93.1% (95% CI 86.49–99.63%) for laBCC. Adverse events (AEs) in >30% of pts were muscle spasms, alopecia, dysgeusia, weight decrease, fatigue, nausea, and amenorrhea (33.3%; 2/6 pts). Serious AEs were reported in 32 pts (31%). No additional fatal AEs were reported since the prior data cut (n=7, 7%; none considered related to vismodegib). Conclusions: This 6-mo update of I-A efficacy and safety endpoints from the ERIVANCE BCC study supports the significant clinical benefit of vismodegib in both laBCC and mBCC reported at the primary analysis. Median DOR and PFS increased numerically with follow-up. The AE profile was consistent with the prior data cut. These results further support the efficacy of vismodegib for treatment of advanced BCC. [Table: see text]" @default.
- W2321877253 created "2016-06-24" @default.
- W2321877253 creator A5007005578 @default.
- W2321877253 creator A5010628808 @default.
- W2321877253 creator A5022173747 @default.
- W2321877253 creator A5023949142 @default.
- W2321877253 creator A5030774402 @default.
- W2321877253 creator A5044736874 @default.
- W2321877253 creator A5049996335 @default.
- W2321877253 creator A5065917441 @default.
- W2321877253 creator A5076660969 @default.
- W2321877253 creator A5083416082 @default.
- W2321877253 date "2012-05-20" @default.
- W2321877253 modified "2023-10-13" @default.
- W2321877253 title "Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update." @default.
- W2321877253 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.8579" @default.
- W2321877253 hasPublicationYear "2012" @default.
- W2321877253 type Work @default.
- W2321877253 sameAs 2321877253 @default.
- W2321877253 citedByCount "2" @default.
- W2321877253 countsByYear W23218772532012 @default.
- W2321877253 countsByYear W23218772532013 @default.
- W2321877253 crossrefType "journal-article" @default.
- W2321877253 hasAuthorship W2321877253A5007005578 @default.
- W2321877253 hasAuthorship W2321877253A5010628808 @default.
- W2321877253 hasAuthorship W2321877253A5022173747 @default.
- W2321877253 hasAuthorship W2321877253A5023949142 @default.
- W2321877253 hasAuthorship W2321877253A5030774402 @default.
- W2321877253 hasAuthorship W2321877253A5044736874 @default.
- W2321877253 hasAuthorship W2321877253A5049996335 @default.
- W2321877253 hasAuthorship W2321877253A5065917441 @default.
- W2321877253 hasAuthorship W2321877253A5076660969 @default.
- W2321877253 hasAuthorship W2321877253A5083416082 @default.
- W2321877253 hasConcept C126322002 @default.
- W2321877253 hasConcept C143998085 @default.
- W2321877253 hasConcept C2778539099 @default.
- W2321877253 hasConcept C2778804307 @default.
- W2321877253 hasConcept C2779545874 @default.
- W2321877253 hasConcept C3019992690 @default.
- W2321877253 hasConcept C502942594 @default.
- W2321877253 hasConcept C54355233 @default.
- W2321877253 hasConcept C62478195 @default.
- W2321877253 hasConcept C71924100 @default.
- W2321877253 hasConcept C86803240 @default.
- W2321877253 hasConcept C88498014 @default.
- W2321877253 hasConcept C98274493 @default.
- W2321877253 hasConceptScore W2321877253C126322002 @default.
- W2321877253 hasConceptScore W2321877253C143998085 @default.
- W2321877253 hasConceptScore W2321877253C2778539099 @default.
- W2321877253 hasConceptScore W2321877253C2778804307 @default.
- W2321877253 hasConceptScore W2321877253C2779545874 @default.
- W2321877253 hasConceptScore W2321877253C3019992690 @default.
- W2321877253 hasConceptScore W2321877253C502942594 @default.
- W2321877253 hasConceptScore W2321877253C54355233 @default.
- W2321877253 hasConceptScore W2321877253C62478195 @default.
- W2321877253 hasConceptScore W2321877253C71924100 @default.
- W2321877253 hasConceptScore W2321877253C86803240 @default.
- W2321877253 hasConceptScore W2321877253C88498014 @default.
- W2321877253 hasConceptScore W2321877253C98274493 @default.
- W2321877253 hasLocation W23218772531 @default.
- W2321877253 hasOpenAccess W2321877253 @default.
- W2321877253 hasPrimaryLocation W23218772531 @default.
- W2321877253 hasRelatedWork W1583369240 @default.
- W2321877253 hasRelatedWork W1964474743 @default.
- W2321877253 hasRelatedWork W1965431780 @default.
- W2321877253 hasRelatedWork W1974941552 @default.
- W2321877253 hasRelatedWork W2071250613 @default.
- W2321877253 hasRelatedWork W2101616608 @default.
- W2321877253 hasRelatedWork W2165741711 @default.
- W2321877253 hasRelatedWork W2312451380 @default.
- W2321877253 hasRelatedWork W2471311344 @default.
- W2321877253 hasRelatedWork W2513585179 @default.
- W2321877253 hasRelatedWork W2588244614 @default.
- W2321877253 hasRelatedWork W2740460454 @default.
- W2321877253 hasRelatedWork W2752849067 @default.
- W2321877253 hasRelatedWork W2890724411 @default.
- W2321877253 hasRelatedWork W2962888042 @default.
- W2321877253 hasRelatedWork W3002730254 @default.
- W2321877253 hasRelatedWork W3108094546 @default.
- W2321877253 hasRelatedWork W3212554693 @default.
- W2321877253 hasRelatedWork W90736730 @default.
- W2321877253 hasRelatedWork W2267266577 @default.
- W2321877253 isParatext "false" @default.
- W2321877253 isRetracted "false" @default.
- W2321877253 magId "2321877253" @default.
- W2321877253 workType "article" @default.